Work

Table S2 from RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

Year: 2023

Type: other

Abstract: Treatment-emergent adverse events (occurring in 20% or more patients) and adverse events of special interest by baseline EGFR-activating mutation subgroup (safety population).

DOI: 10.1158/1078-0432.23459202

Authors: Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin-Yuan Shih, Luis Paz-Ares, Bente Frimodt-Moller, Annamaria H. Zimmermann, Sameera Wijayawardana, Carla Visseren-Grul, Martin Reck

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4380028583

Cites:

Cited by:

Related to: 10